In September 2025, a University College London research group announced AMT-130, the first gene silencing therapy for Huntington’s disease (HD), a fatal hereditary neurodegenerative disorder that until then had no treatment capable of altering its course. Bianca Voltmer explores how AMT-130 works, who it may benefit most, and the difficult tradeoffs patients and families face when considering it. AMT-130 delivers an engineered microRNA directly into the brain via a one-time surgical infusion, where it reduces levels of the toxic huntingtin protein responsible for HD’s progression. Clinical results suggest the therapy can slow cognitive decline by up to 75%, effectively stretching one year of expected deterioration into four. Voltmer explains that this marks a fundamental shift in HD treatment, moving away from simply managing symptoms toward genuinely modifying the disease itself. Still, AMT-130 comes with costs and serious risks. The surgery lasts up to 18 hours, carries a price tag of $1 to $4 million before insurance, and is associated with side effects ranging from severe headaches to suicidal ideation. Voltmer argues that these tradeoffs are most justifiable for early-stage HD patients, who stand to gain the most from slowing progression before significant neurological damage has occurred. For middle- to late-stage patients, she is more skeptical. That skepticism is deeply personal: watching her grandmother struggle through the side effects of late-stage Parkinson’s treatment shaped how she thinks about aggressive intervention. 

Photo: Photo Courtesy of iStock File ID: 696241690